{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:52:42Z","timestamp":1784915562603,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007613","name":"Ankara \u00dcniversitesi","doi-asserted-by":"publisher","award":["TYL-2022\\u20132581"],"award-info":[{"award-number":["TYL-2022\\u20132581"]}],"id":[{"id":"10.13039\/100007613","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jpba.2025.116944","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T02:30:33Z","timestamp":1746239433000},"page":"116944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Development of HPLC methodology for quantification of naltrexone and 6\u03b2-naltrexol in human plasma and its potential in alcohol use disorder treatment monitoring"],"prefix":"10.1016","volume":"263","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4211-3981","authenticated-orcid":false,"given":"Ceren H.","family":"Bozmaoglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenan Can","family":"Tok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Danisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Sinan","family":"Suzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Gumustas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2025.116944_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108299","article-title":"Neurosteroids (allopregnanolone) and alcohol use disorder: from mechanisms to potential pharmacotherapy","volume":"240","author":"Gatta","year":"2022","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.jpba.2025.116944_bib2","unstructured":"WHO, Global Status Report on Alcohol and Health, 2018."},{"issue":"17","key":"10.1016\/j.jpba.2025.116944_bib3","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1001\/jama.2022.4308","article-title":"Alcohol-related deaths during the COVID-19 pandemic","volume":"327","author":"White","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jpba.2025.116944_bib4","unstructured":"SAMHSA, Medication for the Treatment of Alcohol Use Disorder: A Brief Guide, 2015."},{"issue":"1","key":"10.1016\/j.jpba.2025.116944_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41398-019-0591-6","article-title":"Developing neuroscience-based treatments for alcohol addiction: a matter of choice?","volume":"9","author":"Heilig","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jpba.2025.116944_bib6","first-page":"126","article-title":"for Substance abuse, incorporating alcohol pharmacotherapies into medical practice","volume":"114","author":"Center","year":"2009","journal-title":"Cent. Subst. Abus. Treat."},{"issue":"6","key":"10.1016\/j.jpba.2025.116944_bib7","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/adb.12425","article-title":"Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies","volume":"22","author":"Hendershot","year":"2017","journal-title":"Addict. Biol."},{"key":"10.1016\/j.jpba.2025.116944_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109376","article-title":"The life and times of endogenous opioid peptides: updated understanding of synthesis, spatiotemporal dynamics, and the clinical impact in alcohol use disorder","volume":"225","author":"Margolis","year":"2023","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.jpba.2025.116944_bib9","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.addbeh.2012.09.015","article-title":"Involvement of the mu-opioid receptor gene polymorphism A118G in the efficacy of detoxification of alcohol dependent patients","volume":"38","author":"Marini","year":"2013","journal-title":"Addict. Behav."},{"issue":"2","key":"10.1016\/j.jpba.2025.116944_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0376-8716(75)90012-5","article-title":"Narcotic and narcotic antagonist pKa's and partition coefficients and their significance in clinical practice","volume":"1","author":"Kaufman","year":"1975","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10.1016\/j.jpba.2025.116944_bib11","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2165\/00003088-199733050-00003","article-title":"Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users","volume":"33","author":"Quinn","year":"1997","journal-title":"Clin. Pharmacokinet."},{"issue":"February","key":"10.1016\/j.jpba.2025.116944_bib12","first-page":"36","article-title":"Quantitative determination of naltrexone, 6\u03b2-naltrexol and 2-hydroxy-3-methoxy-6\u03b2-naltrexol (HMN) in human plasma, red blood cells, saliva and urine by gas liquid chromatography","volume":"28","author":"Verebey","year":"1981","journal-title":"NIDA Res. Monogr. Ser."},{"key":"10.1016\/j.jpba.2025.116944_bib13","unstructured":"S.J. Porter, A.A. Somogyi, J.M. White, Naltrexone in Human Liver Cytosol, Science 2000."},{"issue":"3","key":"10.1016\/j.jpba.2025.116944_bib14","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00216-009-3301-z","article-title":"Determination of naltrexone and 6\u03b2-naltrexol in human blood: comparison of high-performance liquid chromatography with spectrophotometric and tandem-mass-spectrometric detection","volume":"396","author":"Br\u00fcnen","year":"2010","journal-title":"Anal. Bioanal. Chem."},{"issue":"1","key":"10.1016\/j.jpba.2025.116944_bib15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13722-022-00345-y","article-title":"Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates","volume":"17","author":"Terasaki","year":"2022","journal-title":"Addict. Sci. Clin. Pr."},{"issue":"1","key":"10.1016\/j.jpba.2025.116944_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12876-023-02656-z","article-title":"Alcohol treatment discussions and clinical outcomes among patients with alcohol-related cirrhosis","volume":"23","author":"Alexandre","year":"2023","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.jpba.2025.116944_bib17","doi-asserted-by":"crossref","DOI":"10.1186\/1756-0500-5-439","article-title":"Analysis of naltrexone and its metabolite 6-beta-naltrexol in serum with high-performance liquid chromatography","volume":"5","author":"Hein\u00e4l\u00e4","year":"2012","journal-title":"BMC Res. Notes"},{"issue":"3","key":"10.1016\/j.jpba.2025.116944_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/1099-0801(200005)14:3<151::AID-BMC941>3.0.CO;2-E","article-title":"High-performance liquid chromatographic determination of naltrexone in plasma of hemodialysis patients","volume":"14","author":"Kambia","year":"2000","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2025.116944_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114615","article-title":"Monitoring alcohol-use-disorder medication compliance by LC-MS\/MS determination of urinary ethyl glucuronide, acamprosate, naltrexone, and 6beta-naltrexol using zirconia-based hybrid solid-phase extraction","volume":"212","author":"Kim","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.116944_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.talo.2023.100183","article-title":"Determination of opiates in urine samples using a composite of covalent organic framework and polypyrrole as a sorbent for microextraction in a packed syringe combined with HPLC\/UV","volume":"7","author":"Zanganeh","year":"2023","journal-title":"Talanta Open"},{"issue":"1","key":"10.1016\/j.jpba.2025.116944_bib21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11419-020-00561-8","article-title":"Development and validation of quantitative analytical method for 50 drugs of antidepressants, benzodiazepines and opioids in oral fluid samples by liquid chromatography\u2013tandem mass spectrometry","volume":"39","author":"Arantes","year":"2020","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.jpba.2025.116944_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.chroma.2017.10.049","article-title":"On-chip pulsed electromembrane extraction as a new concept for analysis of biological fluids in a small device","volume":"1527","author":"Karami","year":"2017","journal-title":"J. Chromatogr. A"},{"issue":"1-2","key":"10.1016\/j.jpba.2025.116944_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jchromb.2008.08.021","article-title":"An automated, Highly sensitive LC-MS\/MS assay for the quantification of the opiate antagonist naltrexone and its major metabolite 6beta-naltrexol in dog and human plasma","volume":"874","author":"Clavijo","year":"2008","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"1","key":"10.1016\/j.jpba.2025.116944_bib24","first-page":"14","article-title":"Selective, and sensitive method for the analysis of naltrexone and 6\u03b2-naltrexol in urine","volume":"14","author":"Strickland","year":"2016","journal-title":"Spectrosc. Suppl."},{"issue":"4","key":"10.1016\/j.jpba.2025.116944_bib25","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/jat\/bku019","article-title":"Naltrexone metabolism and concomitant drug concentrations in chronic pain patients","volume":"38","author":"Liu","year":"2014","journal-title":"J. Anal. Toxicol."},{"issue":"4","key":"10.1016\/j.jpba.2025.116944_bib26","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.talanta.2006.07.035","article-title":"Simultaneous analysis of naltrexone and its major metabolite, 6-beta-naltrexol, in human plasma using liquid chromatography-tandem mass spectrometry: application to a parent-metabolite kinetic model in humans","volume":"71","author":"Yun","year":"2007","journal-title":"Talanta"},{"key":"10.1016\/j.jpba.2025.116944_bib27","article-title":"on AGREEprep an analytical greenness metric for sample preparation","volume":"3","author":"Pena-Pereira","year":"2022","journal-title":"Adv. Sample Prep."},{"issue":"19","key":"10.1016\/j.jpba.2025.116944_bib28","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.1039\/D3GC02347H","article-title":"Blue applicability grade index (BAGI) and software: a new tool for the evaluation of method practicality","volume":"25","author":"Manousi","year":"2023","journal-title":"Green. Chem."},{"key":"10.1016\/j.jpba.2025.116944_bib29","unstructured":"J. P\u0142otka-Wasylka, Red Analytical Performance Index (RAPI). \u3008https:\/\/mostwiedzy.pl\/en\/justyna-plotka-wasylka,647762-1\/rapi\u3009, 2024 (Accessed 19 Mar 2025.2025)."},{"issue":"1","key":"10.1016\/j.jpba.2025.116944_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10337-018-3670-6","article-title":"The history of the core-shell particles and applications in active pharmaceutical ingredients via liquid chromatography","volume":"82","author":"Gumustas","year":"2019","journal-title":"Chromatographia"},{"key":"10.1016\/j.jpba.2025.116944_bib31","unstructured":"F.D.A., Bioanalytical Method Validation Guidance for Industry. \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry\u3009, 2018."},{"key":"10.1016\/j.jpba.2025.116944_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2025.116805","article-title":"Development of a sample preparation and analysis method for therapeutic monitoring of diazepam and major metabolite in alcohol withdrawal syndrome treatment","volume":"260","author":"Tok","year":"2025","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525002857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525002857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:16:04Z","timestamp":1762308964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708525002857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":32,"alternative-id":["S0731708525002857"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116944","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of HPLC methodology for quantification of naltrexone and 6\u03b2-naltrexol in human plasma and its potential in alcohol use disorder treatment monitoring","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116944","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116944"}}